OncoMatch/Clinical Trials/NCT04337580
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Is NCT04337580 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Omeprazole 80 mg twice daily for prostate cancer.
Treatment: Omeprazole 80 mg twice daily — The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Investigators believe omeprazole may help the other medications work.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: taxane (docetaxel) — castrate refractory
Lab requirements
Blood counts
absolute neutrophil count >1,200/mcl, platelets >75,000/mcl
Kidney function
creatinine <2.5 x institutional upper limit of normal
Liver function
total bilirubin = within normal institutional limits; ast(sgot)/alt(sgpt) <2.5 x institutional upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- W.G. Bill Hefner VA Medical Center · Salisbury, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify